NASDAQ:URGN

UroGen Pharma Earnings Date, Estimates & History

$17.63
+0.15 (+0.86 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.48
Now: $17.63
$18.48
50-Day Range
$17.48
MA: $19.49
$21.48
52-Week Range
$17.01
Now: $17.63
$30.89
Volume92,393 shs
Average Volume205,931 shs
Market Capitalization$368.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32

Earnings

UroGen Pharma (NASDAQ:URGN) Earnings Information

UroGen Pharma last posted its earnings results on March 17th, 2021. The reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by $0.01. UroGen Pharma has generated ($5.12) earnings per share over the last year. UroGen Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 6th, 2021 based off prior year's report dates.

UroGen Pharma Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

UroGen Pharma (NASDAQ:URGN) Earnings Estimates

2021 EPS Consensus Estimate: ($5.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20212($1.45)($1.33)($1.39)
Q2 20212($1.37)($1.22)($1.30)
Q3 20212($1.40)($1.18)($1.29)
Q4 20211($1.06)($1.06)($1.06)

UroGen Pharma (NASDAQ URGN) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
5/6/2021
(Estimated)
       
3/17/202112/31/2020($1.37)($1.38)($1.38)Transcript
11/9/20209/30/2020($1.47)($1.31)($1.31)$3.21 million$3.46 millionTranscript
8/10/20206/30/2020($1.59)($1.44)($1.44)$0.50 million$0.37 millionTranscript
5/7/20203/31/2020($1.62)($1.79)($1.79)Listen
3/2/202012/31/2019($1.70)($1.86)($1.86)Transcript
11/12/2019Q3($1.26)($1.06)($1.06)Transcript
8/9/2019Q2 2019($1.20)($1.08)($1.08)$0.02 millionTranscript
5/9/20193/31/2019($1.12)($1.11)($1.11)Transcript
2/28/2019Q4 2018($1.29)($1.46)($1.46)Transcript
11/15/20189/30/2018($1.09)($1.28)($1.28)$0.28 millionN/A
8/14/20186/30/2018($0.89)($1.14)($1.14)$0.36 millionN/A
5/15/20183/31/2018($0.73)($0.88)($0.88)$0.48 millionN/A
3/15/2018n/a($0.65)($0.74)($0.74)$0.33 millionTranscript
11/14/2017Q3 2017$0.08($0.02)($0.02)$7.67 million$7.81 millionN/A
8/14/2017Q2 2017($0.46)($0.70)($0.70)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.